Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip R Greipp

Showing results (31-40 of 113) with videos related to

Pageof 12
Sort By:
Blood|November 8, 2003
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporterDavid Dingli, Kah-Whye Peng, Mary E Harvey, et al.
Mayo Clinic Proceedings|July 17, 2010
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experiencePrashant Kapoor, Patricia T Greipp, Eric W Schaefer, et al.
Experimental Hematology|March 19, 2008
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cellsMichael P Kline, S Vincent Rajkumar, Michael M Timm, et al.
Blood|March 14, 2012
Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)Zhihui Xie, Chandra C Ghosh, Roshni Patel, et al.
Blood|September 27, 2003
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survivalAnne J Novak, Jaime R Darce, Bonnie K Arendt, et al.
British Journal of Haematology|October 9, 2003
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myelomaMichael A Thompson, Thomas E Witzig, Shaji Kumar, et al.
Blood|March 11, 2004
Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myelomaCynthia X Ma, Martha Q Lacy, John F Rompala, et al.
Blood|June 25, 2005
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapyMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
The Lancet. Oncology|October 27, 2009
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialS Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, et al.
British Journal of Haematology|November 20, 2002
Bone marrow angiogenesis in multiple myeloma: effect of therapyShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.
Pageof 12

Showing results (31-40 of 113) with videos related to

Sort By:
Pageof 12
Blood|November 8, 2003
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporterDavid Dingli, Kah-Whye Peng, Mary E Harvey, et al.
Mayo Clinic Proceedings|July 17, 2010
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experiencePrashant Kapoor, Patricia T Greipp, Eric W Schaefer, et al.
Experimental Hematology|March 19, 2008
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cellsMichael P Kline, S Vincent Rajkumar, Michael M Timm, et al.
Blood|March 14, 2012
Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)Zhihui Xie, Chandra C Ghosh, Roshni Patel, et al.
Blood|September 27, 2003
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survivalAnne J Novak, Jaime R Darce, Bonnie K Arendt, et al.
British Journal of Haematology|October 9, 2003
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myelomaMichael A Thompson, Thomas E Witzig, Shaji Kumar, et al.
Blood|March 11, 2004
Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myelomaCynthia X Ma, Martha Q Lacy, John F Rompala, et al.
Blood|June 25, 2005
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapyMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
The Lancet. Oncology|October 27, 2009
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialS Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, et al.
British Journal of Haematology|November 20, 2002
Bone marrow angiogenesis in multiple myeloma: effect of therapyShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.
Pageof 12